372 related articles for article (PubMed ID: 10859447)
1. Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer.
Martínez M; España F; Royo M; Vera CD; Estellés A; Jiménez-Cruz JF; Medina P; Aznar J
Eur Urol; 2000 Jul; 38(1):85-90. PubMed ID: 10859447
[TBL] [Abstract][Full Text] [Related]
2. The proportion of prostate-specific antigen (PSA) complexed to alpha(1)-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 microg/L.
Martínez M; España F; Royo M; Alapont JM; Navarro S; Estellés A; Aznar J; Vera CD; Jiménez-Cruz JF
Clin Chem; 2002 Aug; 48(8):1251-6. PubMed ID: 12142381
[TBL] [Abstract][Full Text] [Related]
3. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
[TBL] [Abstract][Full Text] [Related]
4. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
5. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
España F; Martínez M; Royo M; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF
Eur Urol; 1997; 32(3):268-72. PubMed ID: 9358211
[TBL] [Abstract][Full Text] [Related]
6. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.
Björk T; Piironen T; Pettersson K; Lövgren T; Stenman UH; Oesterling JE; Abrahamsson PA; Lilja H
Urology; 1996 Dec; 48(6):882-8. PubMed ID: 8973671
[TBL] [Abstract][Full Text] [Related]
7. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
9. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Goepel M; Tscholl R
Br J Urol; 1998 Apr; 81(4):532-8. PubMed ID: 9598623
[TBL] [Abstract][Full Text] [Related]
10. [PSA:alpha 1-antichymotrypsin ratio/total PSA in the diagnosis of prostatic cancer in the range of total PSA from 4 to 10 ng/ml].
Martínez Sarmiento M; España F; Royo M; Estellés A; Aznar J; Vera Donoso CD; Medina P; Jiménez Cruz JF
Actas Urol Esp; 2001 Apr; 25(4):269-77. PubMed ID: 11455828
[TBL] [Abstract][Full Text] [Related]
11. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels.
Saika T; Tsushima T; Nasu Y; Kusaka N; Miyaji Y; Takamoto H; Takeda K; Uno S; Kumon H;
Cancer; 2002 Mar; 94(6):1685-91. PubMed ID: 11920529
[TBL] [Abstract][Full Text] [Related]
13. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
14. Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Reiter W; Stieber P; Schmeller N; Nagel D; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4767-70. PubMed ID: 9494604
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
16. Free/total prostate-specific antigen ratio--hope and controversies.
Ravery V; Boccon-Gibod L
Eur Urol; 1997; 31(4):385-8. PubMed ID: 9187894
[TBL] [Abstract][Full Text] [Related]
17. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
Thakur V; Singh PP; Talwar M; Mukherjee U
Dis Markers; 2003-2004; 19(6):287-92. PubMed ID: 15258330
[TBL] [Abstract][Full Text] [Related]
18. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer.
Christensson A; Björk T; Nilsson O; Dahlén U; Matikainen MT; Cockett AT; Abrahamsson PA; Lilja H
J Urol; 1993 Jul; 150(1):100-5. PubMed ID: 7685416
[TBL] [Abstract][Full Text] [Related]
19. Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men.
Sheikh M; Al-Saeed O; Kehinde EO; Sinan T; Anim JT; Ali Y
Int Urol Nephrol; 2005; 37(4):721-6. PubMed ID: 16362587
[TBL] [Abstract][Full Text] [Related]
20. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
